Rockwell Medical Inc (NASDAQ:RMTI) Director Kenneth L. Holt sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $5.98, for a total transaction of $35,880.00. Following the sale, the director now directly owns 17,430 shares of the company’s stock, valued at approximately $104,231.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Rockwell Medical Inc (NASDAQ:RMTI) traded down 0.17% during mid-day trading on Monday, hitting $6.05. 212,114 shares of the stock traded hands. The firm’s 50-day moving average price is $5.94 and its 200-day moving average price is $6.26. The firm’s market cap is $311.74 million. Rockwell Medical Inc has a 52 week low of $3.55 and a 52 week high of $10.58.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Wednesday, March 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.01. Rockwell Medical had a negative net margin of 37.98% and a negative return on equity of 33.60%. The business earned $13.39 million during the quarter, compared to the consensus estimate of $15.45 million. During the same period in the previous year, the business posted ($0.12) earnings per share. Rockwell Medical’s revenue was down 5.3% compared to the same quarter last year. On average, equities analysts forecast that Rockwell Medical Inc will post ($0.19) earnings per share for the current fiscal year.
Your IP Address:
Institutional investors have recently made changes to their positions in the stock. US Bancorp DE acquired a new position in shares of Rockwell Medical during the third quarter worth about $124,000. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Rockwell Medical by 0.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,090 shares of the company’s stock worth $165,000 after buying an additional 100 shares during the last quarter. Cutter & CO Brokerage Inc. acquired a new position in shares of Rockwell Medical during the fourth quarter worth about $166,000. Rehmann Capital Advisory Group boosted its position in shares of Rockwell Medical by 34.2% in the third quarter. Rehmann Capital Advisory Group now owns 31,972 shares of the company’s stock worth $214,000 after buying an additional 8,144 shares during the last quarter. Finally, Balasa Dinverno & Foltz LLC boosted its position in shares of Rockwell Medical by 4.2% in the third quarter. Balasa Dinverno & Foltz LLC now owns 37,300 shares of the company’s stock worth $250,000 after buying an additional 1,500 shares during the last quarter. 21.14% of the stock is currently owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, January 20th.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.